The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The MAPP survey revealed unmet needs in treatment:
*Subset of all patients surveyed. Overall, 24% of all patients said they had been prescribed a traditional oral medication for their disease (eg, cyclosporine, methotrexate, acitretin, or fumaric acid esters) at some point since their diagnosis; of these, 43% were receiving therapy and 57% had discontinued use.
Patients who discontinued traditional oral therapies did so primarily due to concerns about efficacy, safety, and tolerability1
Multiple manifestations impact physical function and contribute substantially to disease burden2-5
Treatment for psoriatic arthritis should address as many of the 6 key
domains as possible, while balancing safety considerations6
OTEZLA | Methotrexate | Sulfasolazine | Leflunomide |
|
|---|---|---|---|---|
| PsA - specific evidence | ||||
| Effectiveness in multiple PsA domains, including dactylitis and enthesitis | ||||
| Evidence of long-term efficacy | ||||
| Proven long-term safety profile | ||||
| Other considerations | ||||
| No label-required laboratory prescreening or ongoing monitoring* | ||||
| Warnings and precautions |
|
|
|
|
aProducts that are available as generic formulations are referred to by the active compound name.
*Regular monitoring is recommended for patients who are underweight at the start of treatment.
Nearly two-thirds of patients on stable conventional DMARDs
continue to have disease activity, suggesting that a majority of
patients may benefit from treatment modification12†
†Observational, cross-sectional study (N = 152) conducted at 2 sites in Amsterdam involving patients with psoriatic arthritis on current or previous conventional DMARD, such as methotrexate or leflunomide, or TNF-inhibitor. Disease activity was defined by the treating rheumatologist (an answer of YES to the question: Do you think there is remaining disease activity in this patient, despite current treatment regimen?) based on physical examination at a routine clinical visit and collected outcome measures (VAS-PhysGlobal, VAS-PhysSkin, and BASDAI).
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DMARD, disease-modifying antirheumatic drug; DRESS, Drug Reaction with Eosinophilia and Systemic Symptoms; MAPP, Multinational Assessment of Psoriasis and Psoriatic Arthritis survey; PsA, psoriatic arthritis; TNF, tumor necrosis factor; VAS, visual analog scale.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.